Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 2/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.30 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11336328 | 0.84 | LMNA (0.33) | LMNAFDPS | |
| SCHEMBL21571158 | 0.82 | BTN3A1 (0.37) | — | |
| SCHEMBL15752030 | 0.82 | SMPD1 (0.32) | SMPD1LMNAFDPSBLMTDP1 | |
| SCHEMBL156446 | 0.81 | BTN3A1 (0.38) | FDPSBLMTDP1 | |
| SCHEMBL9901912 | 0.80 | LMNA (0.31) | LMNA | |
| Pyrophosphoric Acid SCHEMBL5062989 | 0.80 | FDPS (0.42) | FDPSBLMTDP1 | |
| Pyrophosphoric Acid SCHEMBL3890468 | 0.80 | FDPS (0.42) | FDPSBLMTDP1 | |
| Ammonia Solution, Strong SCHEMBL3690678 | 0.80 | BTN3A1 (0.37) | FDPSBLMTDP1 | |
| Ammonia Solution, Strong SCHEMBL3690680 | 0.80 | BTN3A1 (0.37) | FDPSBLMTDP1 | |
| SCHEMBL18486678 | 0.78 | BTN3A1 (0.36) | FDPSBLMTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 330 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12480144-B2 | Cannabinoid synthase variants and methods for their use | CREO INGREDIENTS, INC. (US) | 2025-11-25 | — | — | US | claimed |
| US-12084704-B2 | Methods for producing isobutene from 3-methylcrotonic acid | GLOBAL BIOENERGIES (FR) | 2024-09-10 | — | — | US | claimed |
| CN-117867044-B | Biological enzyme method preparation technology of vitamin MK-4 | 杭州微远生物科技有限公司 | 2024-07-30 | — | — | CN | claimed |
| EP-4392564-A1 | MICROBIAL FERMENTATION FOR THE PRODUCTION OF ISOPRENOID ALCOHOLS AND DERIVATIVES | Lanzatech, Inc. (US) | 2024-07-03 | — | — | EP | claimed |
| CN-110914441-B | Improved process for producing isobutene from 3-methylcrotonic acid | 环球生物能源公司 | 2024-06-28 | — | — | CN | claimed |
| CN-117836419-A | Method for transducing immune cells | 朗泽科技有限公司 | 2024-04-05 | — | — | CN | claimed |
| EP-3622080-B1 | IMPROVED METHODS FOR PRODUCING ISOBUTENE FROM 3-METHYLCROTONIC ACID | GLOBAL BIOENERGIES (FR) | 2024-03-27 | — | — | EP | claimed |
| US-20230383321-A1 | IMPROVED METHOD FOR THE PRODUCTION OF ISOPRENOIDS | BASF SE (DE) | 2023-11-30 | — | — | US | claimed |
| US-20230167468-A1 | CANNABINOID SYNTHASE VARIANTS AND METHODS FOR THEIR USE | CREO INGREDIENTS, INC. | 2023-06-01 | — | — | US | claimed |
| US-20230090600-A1 | MICROBIAL FERMENTATION FOR THE PRODUCTION OF ISOPRENOID ALCOHOLS AND DERIVATIVES | LANZATECH, INC. | 2023-03-23 | — | — | US | claimed |
| US-20120202234-A1 | METHODS AND COMPOSITION FOR ISOPRENOID DIPHOSPHATE SYNTHESIS | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2012-08-09 | — | — | US | claimed |
| US-8153426-B2 | selecting from human peripheral blood mononuclear cells, treating the selected cells with a stimulus isopentenyl pyrophosphate, induce strong primary and secondary T helper cell and cytotoxic T cell responses; biodrugs, or vaccination against tumor, infectious diseases | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2012-04-10 | — | — | US | claimed |
| WO-2011009132-A2 | METHODS AND COMPOSITION FOR ISOPRENOID DIPHOSPHATE SYNTHESIS | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2011-01-20 | — | — | WO | claimed |
| US-20090130074-A1 | PREPARATION OF ANTIGEN-PRESENTING HUMAN GAMMA DELTA T CELLS AND USE IN IMMUNOTHERAPY | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2009-05-21 | — | — | US | claimed |
| EP-1088333-A4 | COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION | MERCK & CO INC (US) | 2005-08-10 | — | — | EP | claimed |
| US-6699850-B2 | ORAL FORMULATION OF A COMBINATION OF NITROGEN-CONTAINING BISPHOSPHONATE OR ITS SALT AND AN ISOPRENOID COMPOUND FOR INHIBITING BONE RESOPRTION IN A MAMMAL WHILE COUNTERACTING THE OCCURRENCE OF ADVERSE GASTROINTESTINAL EFFECT | MERCK & CO., INC. | 2004-03-02 | — | — | US | claimed |
| US-20020082244-A1 | Compositions and methods for inhibiting bone resorption | MERCK & CO., INC. | 2002-06-27 | — | — | US | claimed |
| EP-1088333-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION | Merck & Co., Inc. (US) | 2001-04-04 | — | — | EP | claimed |
| WO-1999067809-A9 | COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION | MERCK & CO INC (US) | 2001-03-22 | — | — | WO | claimed |
| WO-1999067809-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION | MERCK & CO., INC. (US) | 1999-12-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082244-A1 | Compositions and methods for inhibiting bone resorption | SOST, PTEN, ALPI | SMPD1 271/4885LMNA 3178/4885FDPS 498/4885 |
| US-20090130074-A1 | PREPARATION OF ANTIGEN-PRESENTING HUMAN GAMMA DELTA T CELLS AND USE IN IMMUNOTHERAPY | CD4, IFNG, CD74 | SMPD1 1195/4885LMNA 4630/4885FDPS 2888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.